Mayo Pujols is the Chief Technology Officer at Kyverna Therapeutics, where he leads the Company’s Tech Development, Manufacturing, Supply and Sourcing, Patient Operations, and Quality functions. A seasoned professional, Mr. Pujols brings more than 30 years of technical operations experience to his role, with a deep background in leading and scaling late-stage and commercial manufacturing for CAR T-cell therapies and complex biologics across both large-scale and smaller biopharmaceutical companies.

Prior to joining Kyverna, Mr. Pujols served as Chief Operating Officer of Castle Creek Biosciences, where he oversaw late-stage autologous cell therapy operations. He also held the role of CTO at Rocket Pharmaceuticals, where he guided multiple gene therapy programs through key regulatory milestones. Mr. Pujols previously worked as the CEO of Andelyn Biosciences, a contract development and manufacturing organization, where he built and scaled the business to serve cell and gene therapy companies. Earlier in his career, Mr. Pujols held several global technical operations positions, including Global Head of Cell and Gene Therapy at Novartis and Vice President of Global CAR T Operations and Technology at Celgene. He also served in senior roles at Advaxis, Merck, AstraZeneca/MedImmune, and Schering Plough.

Mr. Pujols has a Master of Science from Columbia University and a Bachelor of Engineering from Stevens Institute of Technology.